OakChart

Decoy Therapeutics Inc

DCOYHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.09-0.02 (-1.80%)
2026-11-12 06:16 CET
Market cap
2.60 USD m
Revenue, TTM
0.23 USD m
Net income, TTM
-14.45 USD m
Free cash flow, TTM
-8.37 USD m
EPS diluted, TTM
-47.29
P/E
-
Compare

Price

DCOY against its 20, 50 and 200-day averages
2050200earnings
0.0010.0020.0030.0052.6M105.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DCOYclose 1.0920-day 1.1050-day 1.85200-day 5.161.0952w high

94.7% under the 52-week high of 20.76 on 12 Nov 2025. 52-week low 0.90 on 26 Oct 2026. Last 15 sessions, 37.8% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Profile

DCOY
52-week range, 1% of the way up
0.9020.76

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

Employees11
IPOJan 29, 2015
Beta0.72
ATR, 14d0.15
Rel volume0.01
Short float4.37%
Insider own4.59%
Inst own4.19%

Snapshot

6 groups

Valuation

Index-
Market Cap2.60M
Enterprise Value-5.69M
Income-14.45M
Sales0.23M
Book/sh8.12
Cash/sh3.47
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees11
IPOJan 29, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S11.31
P/B0.13
P/C0.31
P/FCF-
EV/EBITDA-
EV/Sales-24.73
Quick Ratio1.83
Current Ratio1.83
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-47.29
EPS next Y-8.96
EPS next Q-2.59
EPS this Y-
EPS next Y-
EPS next 5Y80.05%
EPS past 3/5Y81.80% 62.32%
Sales past 3/5Y- -
EPS Y/Y TTM91.92%
Sales Y/Y TTM-
EPS Q/Q94.51%
Sales Q/Q-
EarningsAug 14
EPS/Sales Surpr.- -

Ownership

Insider Own4.59%
Insider Trans0.00%
Inst Own4.19%
Inst Trans4.14%
ROA-278.04%
ROE-827.77%
ROIC-334.41%
Gross Margin89.24%
Oper. Margin-2679.30%
Profit Margin-6347.85%
SMA20-0.73%
SMA50-41.16%
SMA200-78.89%
Trades-

Technical

Shs Outstand2.39M
Shs Float2.28M
Short Float4.37%
Short Ratio0.05
Short Interest0.10M
52W High20.76 -94.75%
52W Low0.90 21.11%
Volatility7.29% 8.43%
ATR (14)0.15
RSI (14)36.88
Beta0.72
Rel Volume0.01
Avg Volume2.13M
Volume16,384

Performance

Perf Week-4.39%
Perf Month-12.10%
Perf Quarter-69.12%
Perf Half Y-77.39%
Perf YTD-86.00%
Perf Year-90.73%
Perf 3Y-99.90%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom1.00
Target Price3.00
Prev Close1.11
Price1.09
Change %-1.80%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jan 23, 2026InitiatedLLadenburg ThalmannBuy$2.50+129.4%
Apr 27, 2020InitiatedLLadenburg ThalmannBuy$3.80+248.6%

Peers

Mkt cap
TickerCompanyMkt cap
TRAWTraws Pharma Inc3.84M
COCPCocrystal Pharma Inc19.65M
NNVCNanoViricides Inc35.23M
ENTAEnanta Pharmaceuticals Inc337.86M
ALGSAligos Therapeutics Inc15.22M
VRAXVirax Biolabs Group Ltd0.85M
AVIRAtea Pharmaceuticals Inc338.89M
GOVXGeovax Labs Inc1.10M
ARMPArmata Pharmaceuticals Inc144.64M
INOInovio Pharmaceuticals Inc152.51M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
HANISH ARNOLD CDirectorDec 30 '25Sale0.6415105,000Jan 02 05:13 PM
HANISH ARNOLD CDirectorDec 30 '25Sale0.641280Jan 02 05:13 PM
HANISH ARNOLD CDirectorNov 20 '25Buy0.755,0003,7405,015Nov 24 05:08 PM
Rosenblum Mark JExec VP Finance, CFONov 20 '25Buy0.8020,00016,00020,177Nov 20 04:42 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
MEDXHorizon Kinetics Medical ETFAUM: 17.88M

News

latest 14 of 200
  • Decoy Therapeutics Named "R&D Solution of the Year" in 2026 BioTech Breakthrough Awards (GlobeNewswire)
  • Decoy Therapeutics Provides Third Quarter 2026 Business Update (GlobeNewswire) +7.25%
  • Decoy Therapeutics to Present at The Small Cap Showcase (GlobeNewswire) -7.51%
  • Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program (PR Newswire) -7.79%
  • Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release (PR Newswire) +21.09% +24.19%
  • Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules (PR Newswire)
  • Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding (PR Newswire)
  • Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference (Newsfile)
  • Decoy Therapeutics: Q2 Earnings Snapshot (Associated Press) -6.98%
  • Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT Platform (PR Newswire) +5.60%
  • Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV Platform into High Consequence Global Health Threats (PR Newswire) -25.79%
  • Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors (PR Newswire) +7.48%
  • DCOY Stock Nearly Doubled In Value Today Whats Driving This Mega Rally? (Stocktwits) +73.79%
  • Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing (PR Newswire) -6.76%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-4.462--316.80.00--
2025Q42026-03-30-6.480-6.480-16.8760.00-1
2025Q32025-11-13-21.720--316.80.00--
2024Q22024-08-07-426.6-9,648-427.030.000.001
2024Q12024-05-09-9,648-9,648-588.860.000.001
2023Q42024-03-22-316.8--322.420.00--
2023Q22023-08-10-2,059-1,867-2,0610.000.003
2023Q12023-05-11-3,215-3,600-3,2150.000.003
2022Q42023-03-27-4,075-3,103-4,0710.000.002
2022Q32022-11-10-9,230-3,672-9,2310.000.002
2022Q22022-08-08-3,240-3,780-3,1740.000.002
2022Q12022-05-12-4,680-3,240-0.1300.000.001
2021Q42022-03-10-3,240-3,060-3,2670.000.334
2021Q32021-11-04-2,880-2,340-3,0030.001.164
2021Q22021-08-05-2,520-2,040-2,4730.571.283
2021Q12021-05-12-2,160-1,980-2,1821.271.372

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-2,187,000-2,211,000-2,187,0001.010.92
2017FY-1,791,000-1,822,500-1,791,0001.281.31
2018FY-1,098,000--1,048,4910.84-
2019FY-76,320-71,280-76,3953.473.32
2020FY-18,000-21,600-16,9905.235.25
2021FY-11,160-10,710-11,1121.843.14
2022FY-21,427-25,409-21,4240.000.00
2023FY-5,530--5,5320.00-
2024FY-1,042--1,0420.00-
2025FY-57.949-57.949-129.10.00-
2026FY--13.010---
2027FY--19.318---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3R2026-09-29100-2.59-2.59-2.59
2026Q3R2026-03-30100-3.12-3.12-3.12
2026Q3R2026-01-22100-3.12-3.12-3.12
2026Q3E2026-09-29100-2.59-2.59-2.59
2026Q3E2026-03-30100-3.12-3.12-3.12
2026Q3E2026-01-22100-3.12-3.12-3.12
2026Q1R2026-03-30100-4.08-4.08-4.08
2026Q1R2026-01-22100-4.08-4.08-4.08
2026Q1E2026-03-30100-4.12-4.12-4.12
2026Q1E2026-01-22100-4.12-4.12-4.12
2026FYR2026-03-30100-12.96-12.96-12.96
2026FYR2026-01-22100-12.96-12.96-12.96
2026FYE2026-03-30100-13.01-13.01-13.01
2026FYE2026-01-22100-13.01-13.01-13.01

Estimate history

EPS, annual-1790999.776-1048490.869-76394.51-16990.198-11112.119-21423.972-5532.494-1043.057-129.1-47.2851
Period201720182019202020212022202320242025TTM
EPS, quarterly-427.034-136.505-182.844-184.934-81.214-21.765-16.876-4.182-4.462
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual1.2741.9513.4655.2331.8400000.23
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000.228
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0000.0010.0010.0020.0030.0080.5320.532
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0040.0080.0080.0120.0120.0790.5320.5320.532
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.230.000.000.000.001.845.233.471.95
Cost of Goods Sold Incl. D&A0.020.010.000.010.010.02--0.43
Gross Profit0.20-0.01-0.00-0.01-0.011.82--0.41
Selling, General and Administrative Excl. Other6.304.095.7312.8822.9714.6313.0011.713.62
Research and Development2.230.370.777.1715.848.556.914.021.29
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-6.10-4.10-5.73-12.89-22.98-12.81-7.79-8.27-1.68
Interest Expense-----0.000.00-0.00
Unusual Expense8.528.520.000.008.85-0.04-0.44-1.310.00
Net Income Before Taxes-14.45-12.52-5.58-12.54-31.61-12.77-7.35-6.94-1.67
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-14.45-12.52-5.58-12.54-31.61-12.77-7.35-6.94-1.67
Net Income From Continuing Operations-14.45-12.52-5.58-12.54-31.61-12.77-7.35-6.94-1.67
Net Income-14.45-12.52-5.58-12.54-31.61-12.77-7.35-6.94-1.79
EPS (Recurring)-15.95-67.61-1,043.06-5,532.49-17,224.29-11,139.18-17,697.15-86,504.26-1,048,487.22
EPS (Basic, Before Extraordinaries)-47.29-129.10-1,043.06-5,532.49-21,423.97-11,112.12-16,990.20-76,394.51-1,048,490.87
EPS (Diluted)-47.29-129.10-1,043.06-5,532.49-21,423.97-11,112.12-16,990.20-76,394.51-1,048,490.87
EBITDA-6.07-4.09-5.73-12.88-22.97-12.79-7.77-8.25-1.67
Non-Operating Income (Expense)0.170.100.160.350.220.000.000.020.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.580.220.270.520.770.560.270.750.03
Price To Sales Ratio16.80----11.142.713.570.26
Gross Margin89.24----98.96--20.88
Operating Margin-2,679.30-----696.27-148.78-238.53-86.33
Net Margin-6,347.85-----693.84-140.49-200.18-91.90
Shares Outstanding0.530.530.010.000.000.000.000.000.00
Market Capitalization2.602.602.652.563.4422.4221.6717.055.96

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.230.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.000.000.000.000.000.00
Gross Profit0.21-0.01-0.00-0.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other2.622.280.510.890.961.721.491.01
Research and Development1.300.750.110.060.120.080.180.14
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.40-2.28-0.52-0.90-0.97-1.72-1.49-1.01
Unusual Expense0.000.008.520.000.000.000.000.00
Net Income Before Taxes-2.37-2.22-8.98-0.87-0.96-1.71-1.46-0.97
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.37-2.22-8.98-0.87-0.96-1.71-1.46-0.97
Net Income From Continuing Operations-2.37-2.22-8.98-0.87-0.96-1.71-1.46-0.97
Net Income-2.37-2.22-8.98-0.87-0.96-1.71-1.46-0.97
EPS (Recurring)-4.46-4.18-5.67-21.76-81.21-184.93-182.84-136.51
EPS (Basic, Before Extraordinaries)-4.46-4.18-16.88-21.76-81.21-184.93-182.84-136.50
EPS (Diluted)-4.46-4.18-16.88-21.76-81.21-184.93-182.84-136.50
EBITDA-2.39-2.28-0.51-0.89-0.96-1.72-1.49-1.01
Non-Operating Income (Expense)0.030.060.060.020.010.010.020.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.210.210.140.020.020.030.050.18
Price To Sales Ratio16.80-------
Gross Margin94.01-------
Operating Margin-1,055.84-------
Net Margin-1,042.84-------
Shares Outstanding0.530.530.530.080.010.010.010.01
Market Capitalization2.603.474.143.471.911.572.652.08

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments10.712.435.9012.1129.2111.123.746.1333.32
Short Term Receivables0.000.000.001.610.003.860.000.000.01
Inventories0.000.000.000.000.000.000.000.000.43
Other Current Assets0.280.330.620.800.950.820.960.250.78
Total Current Assets10.992.776.5214.5230.1615.804.696.3834.54
Net Property, Plant & Equipment0.040.000.000.000.010.020.030.040.33
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable---0.001.61----
Intangible Assets---0.008.878.878.870.000.00
Other Assets0.030.260.070.130.190.250.310.200.13
Total Assets11.063.026.5914.6540.8324.9313.896.6134.99
Short Term Debt Incl. Current Port. of LT Debt0.000.220.290.000.000.480.500.000.00
Accounts Payable0.940.940.602.861.541.851.790.382.00
Other Current Liabilities4.230.350.411.410.570.441.027.513.84
Total Current Liabilities5.171.511.304.272.112.773.317.885.85
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.04
Total Liabilities5.171.511.304.272.112.773.317.885.89
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5.891.515.2910.3838.7222.1610.58-1.2729.11
Total Shareholders Equity5.891.515.2910.3838.7222.1610.58-1.2729.11
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5.891.515.2910.3838.7222.1610.58-1.2729.11
Total Liabilities & Stockholders Equity11.063.026.5914.6540.8324.9313.896.6134.99
Book Value Per Share11.07188.811,933.186,628.7730,812.8133,506.0784,437.16-562,782.041,471,879.26
Tangible Book Value Per Share11.07188.811,933.186,628.7723,757.9920,100.2613,685.58-562,780.981,471,879.54
Full-Time Employees1122121698422
Price to Book Ratio0.131.750.420.210.580.981.610.641.69
Return on Assets-177.82-116.05-118.12-113.93-38.83-37.87-57.14-8.03-70.12
Return on Equity-338.31-164.02-160.07-128.73-41.94-44.91-69.86-12.00-77.88
Return on Invested Capital-212.58-368.84-237.22-304.37-32.97-33.18-65.55--118.30
Quick Ratio2.131.835.023.4014.295.701.420.815.83
Current Ratio2.131.835.023.4014.295.701.420.815.91

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-14.45-12.52-5.58-12.54-31.61-12.77-7.35-6.94-1.67
Depreciation0.020.010.000.010.010.020.020.020.02
Other Funds (Non Cash)9.098.730.270.6511.640.510.06-0.450.03
Funds from Operations-5.33-3.78-5.30-11.88-19.97-12.23-7.27-7.37-1.62
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.99-1.050.77-0.972.372.03-3.04-4.215.80
Cash from Operating Activities-8.32-4.83-4.53-12.85-17.60-10.20-10.31-11.584.18
Capital Expenditures-0.040.000.000.000.000.00-0.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses1.341.340.000.000.000.000.005.400.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-0.58-0.580.000.00-1.500.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.200.00
Cash from Investing Activities0.720.760.000.00-1.500.00-0.005.610.00
Cash Dividends Paid0.000.000.000.000.000.000.00-0.130.00
Change in Capital Stock15.1012.561.536.921.9928.7718.674.131.44
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.62
Sale of Common Pref Stock15.1012.561.536.921.9928.7718.674.132.05
Proceedsfrom Stock Options15.1012.561.536.921.9927.2914.804.132.05
Issuance or Reduction of Debt, Net0.00-0.22-0.47-0.280.00-0.48-0.97-0.420.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities15.1012.341.066.641.9928.3017.693.581.44
Net Change in Cash7.498.28-3.47-6.21-17.1118.107.38-2.395.61
Free Cash Flow-8.37-4.83-4.53-12.85-17.60-10.20-10.31-11.584.18
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--------0.12
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments8.297.8210.714.810.791.80
Short Term Receivables0.000.000.000.200.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.280.540.280.150.050.22
Total Current Assets8.578.3610.995.160.852.02
Net Property, Plant & Equipment0.400.040.040.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.030.030.030.940.540.32
Total Assets9.008.4211.066.101.392.34
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.11
Accounts Payable1.330.940.941.101.481.47
Other Current Liabilities3.353.614.230.740.740.69
Total Current Liabilities4.684.555.171.852.222.28
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.684.555.171.852.222.28
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.323.885.894.25-0.830.06
Total Shareholders Equity4.323.885.894.25-0.830.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.323.885.894.25-0.830.06
Total Liabilities & Stockholders Equity9.008.4211.066.101.392.34
Book Value Per Share8.127.2911.0753.97-70.215.35
Tangible Book Value Per Share8.127.2911.0753.97-70.215.35
Full-Time Employees--11---
Price to Book Ratio0.130.590.700.82-2.3025.37
Return on Assets-278.04-242.20-177.82-100.54-206.34-154.23
Return on Equity-827.77-661.73-338.31-139.55-660.37-300.16
Return on Invested Capital-54.94-57.37-152.45-20.56--2,763.28
Quick Ratio1.831.842.132.790.380.89
Current Ratio1.831.842.132.790.380.89

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.37-2.22-8.98-0.87-0.96-1.71
Depreciation0.010.010.000.000.000.00
Other Funds (Non Cash)0.210.218.650.020.020.03
Funds from Operations-2.15-2.01-0.32-0.85-0.93-1.67
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.50-0.88-0.81-0.800.070.49
Cash from Operating Activities-2.65-2.89-1.14-1.65-0.86-1.18
Capital Expenditures-0.040.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.001.340.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.00-0.38-0.200.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.040.000.96-0.200.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.160.006.075.86-0.030.66
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.160.006.075.86-0.030.66
Proceedsfrom Stock Options3.160.006.075.86-0.030.66
Issuance or Reduction of Debt, Net0.000.000.000.00-0.11-0.11
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.160.006.075.86-0.140.55
Net Change in Cash0.47-2.895.904.01-1.00-0.64
Free Cash Flow-2.69-2.89-1.14-1.65-0.86-1.18

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.37%0.1M2.3M2.13M
2026-10-154.28%0.1M2.3M2.14M
2026-09-309.40%0.2M1.6M2.16M
2026-09-151.86%0.0M0.6M253.60K
2026-08-312.31%0.0M0.6M246.73K
2026-08-141.67%0.0M0.6M249.29K
2026-07-314.43%0.0M0.6M245.17K
2026-07-154.70%0.0M0.5M229.18K
2026-06-3030.65%0.2M0.5M225.34K
2026-06-150.39%0.0M0.5M19.27K
2026-05-291.80%0.0M0.5M23.37K
2026-05-151.70%0.0M0.5M22.28K
2026-04-302.26%0.0M0.5M24.66K
2026-04-154.65%0.0M0.5M27.95K
2026-03-313.86%0.0M0.5M190.57K
2026-03-135.78%0.0M0.5M191.02K
2026-02-275.11%0.0M0.5M185.55K
2026-02-136.69%0.0M0.5M197.67K
2026-01-307.49%0.0M0.5M318.24K
2026-01-1517.78%0.1M0.5M309.64K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-16EFFECTEffectiveness filing by commission orderSEC
2026-10-16424B3SEC
2026-10-07S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-238-KCurrent report2026-09-22SEC
2026-09-158-KCurrent report2026-09-14SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-14SCHEDULE 13GSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-04DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-14SEC
2026-07-313Initial statement of beneficial ownership of securities2026-07-14SEC
2026-07-24PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-24SEC
2026-07-17EFFECTEffectiveness filing by commission orderSEC
2026-07-17424B3SEC
2026-07-158-KCurrent report2026-07-14SEC
2026-07-10S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-06-298-KCurrent report2026-06-26SEC
2026-06-24EFFECTEffectiveness filing by commission orderSEC
2026-06-15S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-06-05RWRegistration Withdrawal RequestSEC
2026-06-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1200172
2025-1119.74K200

Institutional holders

Manager% owned
COMMONWEALTH EQUITY SERVICES, LLC1.74%
VANGUARD CAPITAL MANAGEMENT LLC0.76%
UBS Group AG0.25%
Tower Research Capital LLC0.05%
SBI Securities Co., Ltd.0.01%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund1.16%
VANGUARD EXTENDED MARKET INDEX FUND0.76%
Fidelity Series Total Market Index Fund0.07%
Horizon Kinetics Medical ETF0.00%

OakChart. DCOY. Cached 15 minutes.